NY-ESO-1 has been a major target of many immunotherapy trials because it is expressed by various cancers and is highly immunogenic. In this study, we have identified a novel HLA-B*1801-restricted CD8 + T cell epitope, NY-ESO-1 88-96 (LEFYLAMPF) and compared its direct-and cross-presentation to that of the reported NY-ESO-1 157-165 epitope restricted to HLA-A*0201. Although both epitopes were readily cross-presented by DCs exposed to various forms of full-length NY-ESO-1 antigen, remarkably NY-ESO-1 88-96 is much more efficiently cross-presented from the soluble form, than NY-ESO-1 157-165 . On the other hand, NY-ESO-1 157-165 is efficiently presented by NY-ESO-1-expressing tumor cells and its presentation was not enhanced by IFN-c treatment, which induced immunoproteasome as demonstrated by Western blots and functionally a decreased presentation of Melan A 26-35 ; whereas NY-ESO-1 88-96 was very inefficiently presented by the same tumor cell lines, except for one that expressed high level of immunoproteasome. It was only presented when the tumor cells were first IFN-c treated, followed by infection with recombinant vaccinia virus encoding NY-ESO-1, which dramatically increased NY-ESO-1 expression. These data indicate that the presentation of NY-ESO-1 88-96 is immunoproteasome dependent. Furthermore, a survey was conducted on multiple samples collected from HLA-B18 + melanoma patients. Surprisingly, all the detectable responses to NY-ESO-1 88-96 from patients, including those who received NY-ESO-1 ISCOMATRIX TM vaccine were induced spontaneously. Taken together, these results imply that some epitopes can be inefficiently presented by tumor cells although the corresponding CD8 + T cell responses are efficiently primed in vivo by DCs cross-presenting these epitopes. The potential implications for cancer vaccine strategies are further discussed.
Introduction
Professional antigen presenting cells (APC) such as dendritic cells (DCs) are responsible for the initial induction, also referred to as priming, of the cellular immune response to pathogens [1] as well as tumors [2] . Various forms of tumor antigens, soluble, cellbound or complexed to specific antibody as immune-complex (IC), are taken up by DCs and their CD8 + T cell (T CD8+ ) epitopes are then presented to antigen-specific T CD8+ -a process called crosspresentation [3, 4, 5] . Various strategies targeting cross-presentation by DCs (such as ISCOMATRIX TM adjuvant [6] ) or stimulating DC differentiation and maturation (e.g. by tumor cells expressing GM-CSF and CD40L [7] ) have been developed and trialed clinically. The validity of such vaccination strategies hinges on the assumption that tumor cells display the same epitopes that are generated by the targeted DCs.
It is well established that mature DCs express the immunoproteasome constitutively [8] . However under non-immune conditions, tumor cells and other somatic cells, express the constitutive proteasome and are generally considered unable to initiate T cell responses via direct presentation due to the lack of co-stimulatory molecule expression [9] . The two types of proteasomes have been shown to cleave peptides with different specificities in vitro [10, 11] , which is thought to lead to altered T cell selection and immune response in vivo to viral antigens [12, 13, 14] , self antigens [11] , as well as tumor antigens [15] . However, none of these studies specifically addressed crosspresentation by DCs, which is more relevant in anti-tumor immunity. It has been demonstrated in mouse models that direct antigen presentation requires continuous antigen synthesis and is typically enhanced with increased intracellular protein degradation [16, 17] ; on the contrary, efficient cross-presentation relies on more stable proteins, large protein fragments [18] or ongoing protein synthesis in the antigen-donating cells [19] . It is also known that the two presentation pathways differ markedly [20] . These differences imply that DC and tumor cell present different repertoires of peptides and some of the differences may lead to disparate patterns of immune responses. For example, if given tumor antigen epitopes are not cross-presented by DCs, related immune responses may not be primed, even when tumor cells abundantly and directly present these epitopes. This scenario could provide a novel opportunity for vaccine intervention. Indeed, we have recently shown that T CD8+ specific for the HLA-B7-resticted NY-ESO-1 60-72 are rarely primed under physiological conditions, yet are easily detected in melanoma patients vaccinated with NY-ESO-1 formulated with ISCOMA-TRIX TM , a saponin and cholesterol based adjuvant that has been shown to target exogenous antigen to the cytosol to enable antigen cross-presentation [21] . Conversely, if tumor antigenic epitopes are cross-presented by DCs, but not directly presented by tumor cells, irrelevant immune responses may be primed. Such responses may not be directly protective, because the activated, tumor antigen-specific T CD8+ would not recognize and eliminate these tumor cells. Furthermore, the elicited T CD8+ could even be detrimental when they are immunodominant, because they may eliminate the cross-presenting DCs upon subsequent vaccinations and thus significantly impair priming of other subdominant T cell responses that may be beneficial to the host, a phenomenon called immunodomination [22, 23] . This scenario has potentially high clinical significance because it is difficult to alter antigen presentation by tumor cells in vivo. To date, few studies demonstrated such difference between direct-and cross-presentation for the same T CD8+ epitopes.
NY-ESO-1 is a cancer testis (CT) antigen expressed by a wide range of human tumors [24, 25, 26] . It is highly immunogenic both in natural disease and in vaccination settings [6, 27] . To understand the underlying mechanisms for such outstanding immunogenicity, the antigen processing and presentation properties of the NY-ESO-1 ISCOMATRIX TM vaccine and other formulations of NY-ESO-1 antigen have been characterized in our laboratories [3, 28] . In the present study, we identified and characterized another unique NY-ESO-1 epitope restricted to HLA-B*1801 (hereafter HLA-B18) from a patient who participated in our NY-ESO-1 ISCOMATRIX TM vaccine trial [6] . The novel T cell epitope, NY-ESO-1 88-96 (LEFYLAMPF), was shown to elicit immunodominant responses and to be efficiently crosspresented by full-length, soluble NY-ESO-1 pulsed monocyte derived dendritic cells (MoDCs). However, this epitope is poorly directly presented by tumor cells expressing both HLA-B18 and NY-ESO-1, unless the immunoproteasome is expressed at high level. Our results demonstrate that not all immunodominant responses may play a direct role to eliminate tumor cells.
Results

Identification and Characterization of a Novel T CD8+
Epitope NY-ESO-1 [88] [89] [90] [91] [92] [93] [94] [95] [96] Presented by HLA-B18
In order to examine the T cell mediated immune response to NY-ESO-1, a systematic 18 mer peptide screen was performed using peripheral blood mononuclear cells (PBMCs) from melanoma patient 8 previously vaccinated with NY-ESO-1 ISCOMA-TRIX TM vaccine [6] . To preserve PBMC samples, pooled 18 mer peptides were used to stimulate NY-ESO-1 specific T cells in the PBMCs. The cultures containing amplified NY-ESO-1-specific T CD8+ were subsequently assessed with individual 18 mer peptides. Our screen showed that the patient had an immunodominant response to NY-ESO-1 in the 79-96 region ( Figure 1A ). Using overlapping 13mer and shorter peptides within the 79-96 sequence in conjunction with peptide prediction algorithms, we narrowed down the likely minimum epitope to 88-96. To confirm this, the NY-ESO-1 88-96 peptide and two other shorter peptides were synthesized and tested by the antigen-specific T cell line. As shown in Figure 1B , at 10 28 M and in the absence of serum proteases, NY-ESO-1 88-96 was able to activate the antigen-specific T CD8+ , but the two peptides with a single amino acid truncation at either end failed to do so, indicating that NY-ESO-1 88-96 is the minimal epitope. Typically 50% of specific T cells within such a T CD8+ line would be activated by as little NY-ESO-1 88-96 peptide as 10 29 M (Figure. 1C ). To characterize which HLA class I allele bound the NY-ESO-1 88-96 peptide, homozygous lymphoblastoid cell lines (LCL) sharing HLA molecule with patient 8, namely 9010, 9039, and 9063, were pulsed with NY-ESO-1 88-96 , washed, and co-cultured with T CD8+ specific for NY-ESO-1 [88] [89] [90] [91] [92] [93] [94] [95] [96] . Clearly these T CD8+ produced IFN-c only when co-cultured with peptide pulsed LCL 9039 ( Figure. 1D ), which shared HLA-B18 and HLA-Cw5 with patient 8. However, LCL 9063 also expressed HLA-Cw5 and was not able to present NY-ESO-1 [88] [89] [90] [91] [92] [93] [94] [95] [96] . We further excluded HLACw7 as the restriction allele using NY-ESO-1 88-96 -pulsed LCL that only shared HLA-Cw7 with the patient, which did not activate the T CD8+ line (data not shown), and concluded that HLA-B*1801 presented NY-ESO-1 [88] [89] [90] [91] [92] [93] [94] [95] [96] .
Having shown that the NY-ESO-1 88-96 -specific T CD8+ response is HLA-B18-restricted, and is immunodominant in patient 8, we investigated whether this response was induced by vaccination. We expanded T cells from PBMC of patient 8 collected before or 70 days after vaccination. Although the response to HLA-B18/NY-ESO-1 88-96 was detectable in the pre-vaccination PBMC sample (0.19% of total T CD8+ , Figure 2A) , it was obviously boosted by the NY-ESO-1 ISCOMATRIX TM vaccine (1.38% of total T CD8+ post vaccination, Figure 2A ). We then examined whether a similar response can be found in PBMCs from other melanoma patients who also express HLA-B18 and had anti-NY-ESO-1 antibody response, which is often associated with anti-NY-ESO-1 T cell response [27] . Antigen-specific T CD8+ were expanded using NY-ESO-1 79-91 peptide and then assessed their antigen-specificity using both tetramer and intracellular cytokine staining (ICS) for IFN-c. As shown in Table 1 , among eight other HLA-B18 + patients, three of the patients had detectable T CD8+ specific for HLA-B18/NY-ESO-1 [88] [89] [90] [91] [92] [93] [94] [95] [96] . Interestingly, all three were incidentally placed in the vaccine groups and the responses were preexisted before vaccination, indicating that the response we detected in patient 8 is not a single case and the anti-NY-ESO-1 88-96 response is likely the immunodominant response associated with HLA-B18. However, the other five samples showed no detectable response to this epitope.
To further characterize this immunodominant T cell response, we conducted a T cell repertoire analysis on T CD8+ specific to HLA-B18/NY-ESO-1 [88] [89] [90] [91] [92] [93] [94] [95] [96] in PBMCs from patient 8. While the majority of T cells used Vb3.1, 5a, 8a and 13, other Vb chains were also used by the antigen-specific T CD8+ ( Figure 2B ), indicating that the NY-ESO-1 88-96 -specific T CD8+ lines used in this study are of polyclonal nature.
NY-ESO-1 88-96 -specific T CD8+ do not Recognize Melanoma Cell Line SK-MEL-8
We have so far shown that the NY-ESO-1 88-96 -specific T CD8+ in most patients were spontaneously generated and can be boosted by vaccination with NY-ESO-1 ISCOMATRIX TM vaccine. It is important to find out whether these T CD8+ are able to recognize tumor cells. To this end, we expanded T CD8+ lines either specific to HLA-B18/NY-ESO-1 88-96 , or HLA-A2/NY-ESO-1 157-165 , a well characterized and naturally presented epitope to serve as a positive control [3, 29] . The two T CD8+ lines were then used to detect direct antigen presentation on a melanoma cell line, SK-MEL-8, which expresses NY-ESO-1 as well as HLA-B18 and HLA-A2. HLA-B18/NY-ESO-1 88-96 and HLA-A2/NY-ESO-1 157-165 tetramers were used in combination with ICS for IFN-c to positively identify the antigen-specific T CD8+ [30] . As expected, peptide-pulsed HLA-B18
+ and HLA-A2 + LCL line 9039 (not shown) and SK-MEL-8 induced IFN-c production from most of the tetramer + T CD8+ specific to either epitope ( Figure. 3A left panels). Importantly, more than half (50.3% and 52.2%) of the NY-ESO-1 157-165 specific T CD8+ were stimulated to produce IFN- Presentation of NY-ESO-1 88-96 is Immunoproteasomedependent and Requires Higher NY-ESO-1 Expression
It is well established that IFN-c treatment of cell lines lead to enhanced antigen processing and presentation, as IFN-c upregulates MHC class I expression and switches constitutive proteasome to immunoproteasome [31] .
The apparent lack of endogenous presentation of HLA-B18/ NY-ESO-1 88-96 by this tumor cell line was further investigated, in combination with IFN-c treatment, using the following two strategies to enhance NY-ESO-1 expression. Firstly, we treated tumor line SK-MEL-8 with DNA hypomethylation agent 5-aza-2-deoxycytidine (5-aza-dC), which has been reported to upregulate cell surface class I and induce or upregulate the expression of different CT antigens in cultured human melanoma lines [32] . Secondly, we infected the cell line with recombinant vaccinia viruses encoding NY-ESO-1 (rVV-NY-ESO-1), which was expected to boost NY-ESO-1 expression. As shown in Figure 4A , the IFN-c treatment increased cell surface class I expression by two fold for SK-MEL-8. However, 5-aza-dC treatment did not increase class I expression. We also performed the treatment under various concentration of 5-aza-dC and similar results were obtained (data not shown). We next used Western blotting to assess the changes in the expression of NY-ESO-1 and the immunoproteasome subunits for the tumor cell line after these treatments. As shown in Figure 4B , SK-MEL-8 expressed NY-ESO-1 at a level that was readily detected and was not further induced by 5-aza-dC treatment. IFN-c treatment did not enhance NY-ESO-1 expression although it clearly induced the expression of the immunoproteasome subunit LMP2, LMP7 and MECL-1 ( Figure 4B ) indicating the switching over from constitutive proteasome to immunoproteasome. Of note, there are faint, similar sized bands revealed by both anti-LMP2 and anti-LMP7 anti-sera before IFN-c treatment. It is possible that these cells may express low level of these subunits under normal culture condition. As expected, rVV-NY-ESO-1 infection of the tumor line greatly boosted NY-ESO-1 expression (,6-fold increase according to the analysis performed using ImageQuant TL software, Amershan Biosciences, data not shown). Importantly, the above-described changes were treatment-specific because the internal loading control of each sample, b-actin, remained unchanged ( Figure 4B top and data not shown).
Using similar T cell lines as shown in Figure 3 , we tested the above treated SK-MEL-8 cells for their antigen presenting capacity. NY-ESO-1 157-165 was again efficiently presented without the treatments. However, the IFN-c-treated SK-MEL-8 showed enhanced antigen-presenting capacity for NY-ESO-1 157-165 [88] [89] [90] [91] [92] [93] [94] [95] [96] in an ICS assay (only ICS results ,0.1% are shown as negative ''-'' indicated by '*'). For patients who showed positive T CD8+ response to this epitope (.0.1%, data not shown) in their post vaccination samples, pre-and post-vaccination PBMC samples were then expanded the same way side-by-side in a second screen intended to determine whether the response was a result of the vaccination. The peptide-specific T CD8+ in the second screen were assessed with the specific HLA-B18/NY-ESO-1 88-96 tetramer. Tetramer results .0.1% of total CD8
+ T cells with a discrete staining pattern are shown; and those results ,0.1% are shown as ''-''. Pre -pre-existed response; Boosted -vaccine-boosted response; ND -not determined, Pre-vac, prior to vaccination; Post-vac, after vaccination. doi:10.1371/journal.pone.0044707.t001 ( Figure 5A ). By contrast, the HLA-B18/NY-ESO-1 88-96 specific T CD8+ were not activated by the same cells, unless they were both IFN-c-treated and rVV-NY-ESO-1 infected ( Figure 5A and the FACS plots in Figure 5B correspond to IFN-c-induced SK-MEL-8 that were either uninfected or infected with rVV-NY-ESO-1 or rVV-GFP). These data imply that the NY-ESO-1 88-96 epitope was processed inefficiently from endogenous antigen and the processing relied on the action of the immunoproteasome rather than the constitutive proteasome.
NY-ESO-1 88-96 is Directly Presented by Tumor Cells Expressing High Level of Immunoproteasome
To exclude the possibility that the above results were the biased outcome of a single melanoma line SK-MEL-8, we collected four other HLA-B18 expressing melanoma lines (for detailed HLA class I typing information, please see Table S1 ). These lines were again left untreated or treated with IFN-c to induce both immunoproteasome and cell surface class I expression; or after IFN-cinduction the cells were further infected with rVV-NY-ESO-1 to either induce or enhance NY-ESO-1 expression. As IFN-c can induce many changes in gene expression, the changes of the immunoproteasome in these cell lines were further monitored functionally by the change of antigen presentation for the HLA-A2/Melan A26-35 epitope as its presentation was reported previously to be impaired by the immunoproteasome [15] . As shown in Figure 6A , although LM-MEL-59, SK-MEL-8 and SK-MEL-25 all expressed NY-ESO-1 antigen and B*1801, they did not present NY-ESO-1 88-96 , unless they are both IFN-c-induced and infected with rVV-NY-ESO-1. This recognition also critically depends on the high avidity of NY-ESO-1 88-96 -specific T cell line as a lower avidity line failed to do so ( Figure S1A , B). The recognition is not an artifact of rVV infection as the same tumor line transiently transfected with pcDNA3-NY-ESO-1 during IFNc-induction also presented this epitope ( Figure S1C ). However, SK-MEL-44 was not able to present NY-ESO-1 88-96 , even under the same treatment regime with similar HLA expression level. It is highly likely that the single AA substitution in B*1803 (Y74D) from B*1801, which is located on the a1-helixes of the peptide-binding cleft, had either prevented NY-ESO-1 88-96 from binding B*1803 or the T cells from recognizing B*1803/NY-ESO-1 88-96 .
Overall, most tested melanoma cell lines expressed detectable immunoproteasome subunit LMP2 and LMP7 although at relatively low level ( Figure 6B) . Interestingly, the cell line LM-MEL-51 presented NY-ESO-1 88-96 quite efficiently even when it was not treated with IFN-c although rVV-NY-ESO-1 infection did further enhance the presentation. However, this cell line expressed high level of LMP2 and LMP7 under normal cell culture conditions and the IFN-c induction did not further induce such expression significantly ( Figure 6B ). Of note, the immunoproteasome expression level in LM-MEL-51 in the absence of IFN-c-induction seemed to be even higher than that of other lines after IFN-c-induction. Importantly, as an internal control the presentation of Melan A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] by the three HLA-A2 positive cell Figure 6C and Figure S1B ). It is possible that the direct presentation of NY-ESO-1 157-165 requires the activity of the constitutive proteasome, perhaps even more so than that required by the Melan A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Taken together, the direct presentation of NY-ESO-1 88-96 by melanoma lines requires high level of both immunoproteasome and NY-ESO-1 expression by tumor lines.
NY-ESO-1 88-96 is Efficiently Cross-presented by MoDC
Knowing that the HLA-B18/NY-ESO-1 88-96 response is often detectable in melanoma patients and that anti-tumor immunity relies on cross-presentation, we hypothesized that this epitope is efficiently cross-presented by DCs. Our previous studies have shown that the antigen formulations influence the efficiency and the pathways of antigen processing and cross-presentation [3, 21, 28] We further demonstrated that these MoDCs first took up the soluble NY-ESO-1 protein followed by endogenous antigen processing to present these epitopes; because under the same conditions with BFA addition, which prevents the HLA from leaving the endoplasm reticulum, cross presentation was abolished ( Figure 7B ). This indicated that in our system the NY-ESO-1 88-96 peptide was generated intracellularly after antigen uptake and not extracellularly by serum proteases. We attempted incubating NY-ESO-1 + tumor cell lysates with MoDCs in such assays with no success (data not shown). We believe that the NY-ESO-1 protein amount might be too little relative to the total cellular protein amount in the tumor lysates.
Discussion
In the process of monitoring T cell responses induced by the NY-ESO-1 ISCOMATRIX TM vaccine, we identified a novel NY-ESO-1 88-96 epitope presented by HLA-B18 molecule. The polyclonal T CD8+ response to this epitope was immunodominant in PBMC from patient 8 and was clearly boosted by our vaccination. The NY-ESO-1 88-96 peptide was efficiently crosspresented by MoDCs pulsed with soluble, recombinant NY-ESO-1 protein, which is different to what has been found for other NY-ESO-1-derived T CD8+ epitopes [3, 21, 28] .
It is well established that direct antigen presentation typically requires ongoing antigen synthesis and proteasome-mediated degradation [16, 17] . However, cross-presentation does not require sustained antigen synthesis and degradation in antigen-donating cells [19] . Given these contrasting requirements between the two presentation pathways and taking into account the peptide cleavage preferences for the constitutive proteasome and the immunoproteasome respectively, there has been surprisingly no reported example demonstrating differential cross-and directpresentation in human APC. Ochsenbein et al [33] showed that, in an artificial tumor antigen system in mice, there was direct priming in the absence of detectable cross-priming for the LCMVderived GP33 epitope expressed on either fibroblasts or EL-4 thymoma cells. In this system, syngeneic tumor cells were used and it was not clear whether or not priming relied on crosspresentation by DCs. Consequently, these authors questioned the physiological significance of cross-presentation in anti-tumor and anti-viral immune responses [33] . In an HLA-A2 transgenic mouse model, Chapatte et al showed that only immunoproteasome deficient DCs were able to prime T CD8+ response to a melanoma differentiation antigen Melan A [34] . However, in this system DCs were infected with a non-replicative lentivirus expressing Melan A before being transferred into naïve mice. Therefore, potentially only direct antigen presentation and priming were assessed, which is likely not the major role DCs play in anti-tumor immunity [34] . Our results clearly demonstrated that cross-presentation of tumor antigens, such as NY-ESO-1 88-96 , occurs readily in cultured MoDCs, especially from soluble form of NY-ESO-1. We are not aware of any other T cell epitope that is more efficiently cross-presented from soluble antigen than complexed antigen forms. This is likely also the case in vivo, because among the nine melanoma patients screened in our study, four had detectable HLA-B18/NY-ESO-1 88-96 responses, while there was no direct presentation of this epitope by most melanoma cells tested. The same melanoma cells were able to present NY-ESO-1 157-165 efficiently under the same conditions ( Figure 5, 6 , and Figure S1B , C) indicating that the amount of NY-ESO-1 expressed by the tumor lines is physiologically sufficient and the antigen processing and presentation machinery is normal. Judging from the NY-ESO-1 amount after rVV-NY-ESO-1 infection ( Figure 4B) , with more than 6-fold increase in expression in the infected SK-MEL-8, it is inconceivable that such level of NY-ESO-1 expression might be achieved in vivo under physiological conditions. Therefore, it is difficult to envisage that the HLA-B18/ NY-ESO-1 88-96 epitope would be ever presented in sufficient level directly on tumor cell surface unless there was a concomitant infection in the tumor-bearing host and the infection resulted in sufficient IFN-c production to induce immunoproteasome in these cells. Interestingly, one of the melanoma lines tested, LM-MEL-51, expressed high level of immunoproteasome and directly presented NY-ESO-1 88-96 ( Figure 6A ). However, it is not clear whether such property was developed in vivo or in vitro. These results not only indicate that the two NY-ESO-1-derived epitopes are processed and presented differently by the intracellular antigen processing and presentation machinery, for both direct-and crosspresentation; but also provide strong evidence that some of the epitopes may not serve as direct target on tumor cells. Figure 7 . NY-ESO-1 88-96 is cross-presented efficiently by DCs from soluble antigen. In A, MoDCs expressing both HLA-A2 and HLA-B18 were cultured for 7 days, and then incubated overnight under the indicated conditions before being co-cultured with the indicated T CD8+ lines for 5 hrs in the presence of BFA. NY-ESO-1 specific T CD8+ activation was assessed by tetramer and ICS. IFN-c producing cells out of total antigen-specific (tetramer positive) T CD8+ were converted to percentages of maximum activation induced by the respective minimum peptide (peptide activation of NY-ESO-1 157-174 T CD8+ line and NY-ESO-1 79-96 T CD8+ line were both 30% to 45% for all three experiments conducted, data not shown) and plotted as ''% Maximum activation''. After data conversion, mean values and standard deviations were calculated from data obtained from three similar experiments. In B, one of the control experiments was shown for APCs that were either pulsed with the corresponding peptide or soluble NY-ESO-1 for one hour followed with BFA addition to demonstrate the nature of intracellular cross-presentation for both T CD8+ epitopes without affecting extracellular peptide presentation. Similar results were obtained twice. doi:10.1371/journal.pone.0044707.g007
In patients with such T cell responses, the tumor cells would therefore behave as natural immune escape mutants, much the same as those that have down regulated their MHC class I expression and lost their antigen-presentation capacity [22, 35] . However, the key difference here maybe that the antigen is likely efficiently taken up by tumor stroma cells (including DCs, macrophages and perhaps others) and the T CD8+ epitopes are then more efficiently displayed. It is not yet known whether stroma elimination by such T CD8+ would be beneficial in humans. However, Spiotto et al. recently demonstrated that murine tumor cells lacking antigen-presenting MHC molecules were controlled by T CD8+ specific for antigens expressed by these tumor cells through the elimination of stroma cells that cross-presented the T cell epitopes from the same tumor antigens [36] . Tumor stroma has been known to play a major role to support tumor growth and sometimes to suppress the immune system [37] . It is therefore possible that T CD8+ specific for epitopes that are efficiently crosspresented might actually play an important role, albeit indirect, to keep tumors in check.
On the other hand, if such T CD8+ responses are immunodominant, such is the case in our patient 8, the subdominant yet tumor-recognizing T CD8+ responses may not be efficiently stimulated due to excess expansion of the immunodominant T CD8+ and, as a result of that, elimination of the cross-presenting DCs. Therefore, T CD8+ with this specificity will further expand and prevent other potentially more beneficial, but subdominant T CD8+ responses from being activated or expanded by the same DCs, a phenomenon termed as immunodomination [23] . There is an example in immunity against influenza A virus in C57BL/6 mouse model, in which vaccinating T CD8+ specific to the immunodominant epitope from acidic polymerase PA [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] caused delayed viral clearance, because this epitope is only generated by DCs [38, 39] due to its strict immunoproteasome dependence [13, 14] .
Biased differential antigen presentation by either the immunoproteasome or the constitutive proteasome has been reported for directly presented, tumor derived epitopes [15, 34, 40, 41] . It has also been recently shown that human MoDCs were more capable of presenting T cell epitopes from melanoma antigens when immunoproteasome expression was knocked down by small interference RNA (siRNA) [42] . However, the later study investigated T cell responses in already 'primed' melanoma patients and did not directly address the role of DC's crosspresentation in anti-tumor immunity, because the tumor antigens studied were all introduced into these DCs by RNA transfection [42] . Our study demonstrated a near 'black-and-white' outcome between direct-and cross-presentation for the NY-ESO-1 88-96 epitope unless high level immunoproteasome is expressed by tumor cells. Importantly, our results may indicate the existence of a whole group of T CD8+ epitopes resulted from differential antigen processing and presentation between DCs and tumor cells. As NY-ESO-1 88-96 -specific T cells are naturally primed and immunodominant in the melanoma patient 8 examined in detail in our study, our findings have important implications for future vaccine design. For example, it might be desired to avoid priming or boosting such T CD8+ by using mutated NY-ESO-1. For instance mutating the anchor residues (89E or 96F) to an Alanine for the NY-ESO-1 88-96 epitope would abrogate the stimulation of its specific T CD8+ . Alternatively, using an antigen form rather than the soluble one may minimize the stimulation to these T CD8+ if their expansion results in immunodomination. Conversely, if these T CD8+ play a positive role through the elimination of stroma cells, as reported in the above mentioned murine system, vaccination with either the soluble form of NY-ESO-1 or the minimal peptide NY-ESO-1 88-96 would then be ideal. Therefore, using full-length tumor antigen as vaccine, although potentially providing broader coverage for T cell epitopes and HLA polymorphism as it may provide all the available epitopes, could be an over-simplified strategy due to the lack of consideration on differential direct-and cross-presentation, not to mention it does not avoid stimulating potential antigenspecific regulatory T cells [43] .
Materials and Methods
Patients
Melanoma patients (listed in Table 1 ) were vaccinated by intramuscular injection with 100 mg NY-ESO-1 ISCOMA-TRIX TM vaccine from LUD99-008 [6] or LUD2002-013 (ClinicalTrials.gov Identifier: NCT00518206) and LUD2003-013 [44] . The LUD99-008 study included patients who received placebo or NY-ESO-1 protein alone and showed that these cohorts were not effectively vaccinated. Full length recombinant NY-ESO-1 protein was produced in E coli and purified in the GMP facility of the Ludwig Institute for Cancer Research at the Memorial Sloan-Kettering Cancer Center (New York, USA). Endotoxin levels ranged between 3-31 EU/ 0.1 mg of protein (limit ,175 EU/0.1 mg protein). ISCOMA-TRIX TM adjuvant (CSL Limited, Victoria, Australia) formulated NY-ESO-1 was generated as described [45, 46] . Immune complexes (ICs) (NY-ESO-1/IC) were generated by mixing NY-ESO-1 protein with anti-NY-ESO-1 mAb ES121 at a 1:2 molar ratio in serum-free RPMI-1640 at 37uC for 30 min as previously described [3] .
Cell Lines, MoDCs, T Cell Culture and Media
All cell lines are maintained in complete medium RF-10 consisting of RPMI-1640 supplemented with 2 mM Glutamax, antibiotics, 10 mM HEPES (Invitrogen, Carlsbad, CA), 1% nonessential amino acids and 10% fetal calf serum (FCS, Thermo Trace, Melbourne, Australia). The SK-MEL-8, SK-MEL-25 [47] and SK-MEL-44 [48] melanoma lines were obtained from the Memorial Sloan-Kettering Cancer Center. LM-MEL-51 and LM-MEL-59 melanoma cell lines were established in our laboratory from melanoma biopsies. Epstein-Barr virus (EBV) transformed, homozygous LCL 9010, 9063 and 9039 were made available from the 10 th International HLA Workshop (New York). PBMCs were prepared from whole blood by Ficoll-Paque centrifugation. T cell lines were generated using RF-10 containing 25 U/ml interleukin- [49] . T cell lines were used at least 12 days after culture. In some cases, tetramer enriched antigen-specific T cells were further expanded by PHA and allogeneic feeders. T cell specificity was confirmed by tetramer staining. For the 18 mer screen, PBMC from patient 8, postvaccination (70 days) with NY-ESO-1 ISCOMATRIX TM vaccine, were cultured for 13 days with pooled overlapping NY-ESO-1 18 mer peptides (3 or 4 peptides per pool) and then tested for responsiveness to individual 18 mer peptide within the pool by ICS for IFN-c [50] . Pre-and post-vaccination PBMCs from patients who received NY-ESO-1 ISCOMATRIX TM vaccine were also tested in parallel to determine whether the B18-restricted, NY-ESO-1 88-96 -specific response was vaccinated or occurred naturally. MoDC were generated from CD14
+ monocytes enriched by MACS beads (Miltenyi Biotec, Auburn, CA) in the presence of 10 ng/mL IL-4 and 20 ng/mL GM-CSF for 6 days [3] .
IFN-c and 5-aza-2-deoxycytidine Treatment of Tumor Cell Line
The melanoma cell line was cultured in either RF-10 or RF-10 plus 50 ng/ml recombinant human IFN-c (PeproTech) for 48 hrs before being used as APCs. 5-aza-2-deoxycytidine (5-aza-dC) was purchased from Sigma-Aldrich. Melanoma cells were pulsed with 0.5 mM 5-aza-dC every 24 h for 3 days as previously described [32] , then used for the indicated experiments and for FACS assessment of their surface Class I molecules using mouse monoclonal antibodies (as hybridoma culture supernatants) BB7.2 (HLA-A2), Bw6 (B18) and W6/32 (pan-class I molecules). FITC conjugated secondary antibody was used for BB7.2 and Bw6 and PE-conjugated secondary antibody was used for W6/32 readout.
Antigen Pulsing and Recombinant Vaccinia Virus Infections
For peptide pulsing, cells were incubated with 10 26 M peptide for 1 hour at room temperature, washed extensively before being incubated with specific T CD8+ . Recombinant vaccinia virus (rVV) encoding NY-ESO-1 (rVV-NY-ESO-1) or Green Fluorescent Protein (rVV-GFP) were gifts from Dr. Lloyd Old (Ludwig Institute for Cancer Research, New York, USA) and Drs Jonathan Yewdell and Jack Bennink (National Institute of Health, Bethesda, Maryland, USA), respectively. Cells were incubated with rVV at a multiplicity of infection (MOI) of 10 for 4 hours at 37uC. Infected cells were then incubated with T CD8+ lines for antigen presentation readout.
Western Blotting
Cells were lysed in 1% Triton-X (Sigma-Aldrich), and SDS-PAGE analyses were performed. The proteins were transferred electrophoretically to a polyvinylidene difluoride membrane (Millipore). Separate Western blots were performed for NY-ESO-1, LMP2, LMP7 and MECL-1 expression. All blots used either b-actin or GAPDH as loading control. After transfer, the membranes were incubated with the primary anti-b-actin or GAPDH (abcam) plus anti-NY-ESO-1 mAb (ES121, [50] ), or the anti-LMP2 polyclonal rabbit anti-serum (abcam), or the anti-LMP7 polyclonal rabbit anti-serum (abcam), or the anti-MECL-1 polyclonal rabbit anti-serum (BIOMOL) at 4uC overnight. All anti-sera were used at 1:2000 dilutions. The membranes were washed in PBS, peroxidase-labeled sheep anti-rabbit immunoglobulins or sheep anti-mouse immunoglobulins for NY-ESO-1 (Silenus Labs) were added at a 1/2500 dilution in PBS with 0.05% Tween 20. After further washing, the proteins were visualized radiographically using an electrochemiluminescence (ECL Plus) substrate (Amersham Biosciences) using a STORM phosphoimager.
T Cell Function Assay
ICS was used in combination with tetramer staining as previously reported by our group [30] . Briefly, cultured T cells were re-stimulated with peptides for 4 hours in the presence of 10 mg/mL Brefeldin A (BFA, Sigma-Aldrich). The cells were then stained with tetramer, anti-CD4 and anti-CD8, fixed with 1% paraformaldehyde (ProSciTech, Queensland, Australia) and further stained with anti-IFN-c in the presence of 0.2% saponin (Sigma-Aldrich). Up to 30,000 events were recorded on a FACS instrument and analyzed using FlowJo software.
For peptide titrations, 10 5 cultured T cells were incubated for 4 hours in the presence of 10 mg/mL BFA and serial dilutions of peptide followed by ICS readout. In direct presentation assays, 10 5 T cells were co-cultured with 5610 4 tumor cells for 4 hours in the presence of 10 mg/mL BFA followed by ICS readout. For cross presentation, MoDCs were incubated overnight with 2 mg NY-ESO-1 protein, NY-ESO-1 ISCOMATRIX TM vaccine or NY-ESO-1/IC with 1 mg/mL CD40L-trimer (a kind gift from Amgen) [3, 28] , in the presence or absence of 5 mg/mL BFA. Tetramer and IFN-c double positive cells were used to calculate the percentages of activated, antigen-specific T CD8+ . Cells pulsed for 1 hour with NY-ESO-1 88-96 peptide and washed before incubation with T cells served as positive controls. For assessing TCR Vb usage of peptide-specific T CD8+ , peptide-expanded T cells from patient 8 were first activated with NY-ESO-1 88-96 peptide, then split into multiple wells and stained with anti-CD8 and a panel of antibodies specific to various TCR Vb families separately followed with ICS for IFN-c. Figure S1 T CD8+ line from patient 102 is of lower avidity and extra NY-ESO-1 expression via transfection also enhances NY-ESO-1 88-96 presentation. T cell lines were established using PBMC samples from Patient 8 or 102 under similar conditions. The early cultures were then enriched through tetramer-guided sorting and further expanded using PHA nonspecific stimulation. Various tumor lines were either untreated, or treated for 48 hrs with IFN-c alone, rVV-NY-ESO-1 infected for 5 hrs, or doubly treated with IFN-c followed by rVV-NY-ESO-1 infection before being used as APC to stimulate T cell lines either specific for A2/NY-ESO-1 157-165 or B18/NY-ESO-1 [88] [89] [90] [91] [92] [93] [94] [95] [96] . In A, peptide titration assay was performed by ICS without tetramer staining. The purity of the T cell lines were: patient 8 NY-ESO-1 88-96 line 88%; patient 102 NY-ESO-1 88-96 line 42%; and the NY-ESO-1 157-165 line 66%. B, for the direct presentation, ICS combined with specific tetramer staining was conducted simultaneously as the titration assay shown in A. In C, SK-MEL-8 cells were either untreated, or induce with IFN-c, or transiently transfected (without selection) with pc3DNA-NY-ESO-1, 5 hrs later induced with IFN-c for 48 hrs before being used as APC. This was conducted on the same day using the same patient 8 NY-ESO-1 88-96 T cell line as that in A and B. Similar results were obtained twice. (TIF) 
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